pharmaphorum June 11, 2023
The US government has more than doubled the size of the latest list of medicines subject to enforced rebates if their prices rise higher than inflation in a new update.
The original version of the list compiled by the US Centres for Medicare and Medicaid Services (CMS) covered 27 drugs, which was reduced to 20 a few weeks later with some prominent new therapies including Gilead Sciences CAR-T therapies Yescarta (axicabtagene ciloleucel) and Tecartus (brexucabtagene autoleucel) for blood cancers taken off.
The latest list stands at 43 medicines, with some of the additions including Seagen’s Adcetris (brentuximab vedotin) for lymphomas, Amgen’s leukaemia therapy Blincyto (blinatumomab), and Amgen/AstraZeneca’s recently-approved severe asthma therapy Tezspire (tezepelumab).
Amgen has been hit particularly hard this...
Today's Sponsors
Today's Sponsor